Core Viewpoint - The approval of SYH2072, a novel class I chemical drug developed by the company, by the National Medical Products Administration of China for clinical trials signifies a significant advancement in the treatment of uncontrolled hypertension and primary aldosteronism [1] Group 1: Product Development - SYH2072 is a highly selective and potent aldosterone synthase inhibitor (ASI) that effectively lowers plasma aldosterone levels without affecting cortisol levels [1] - The approved clinical indications for SYH2072 include uncontrolled hypertension and primary aldosteronism [1] - Preclinical studies demonstrate that SYH2072 selectively inhibits aldosterone synthase activity, significantly reducing plasma aldosterone levels in animal disease models and dose-dependently lowering blood pressure in hypertensive models [1] Group 2: Pharmacokinetics and Safety - The product exhibits favorable pharmacokinetic (PK) characteristics and safety, positioning it as a potential best-in-class drug [1] - The company has submitted multiple patent applications for SYH2072 both domestically and internationally [1] Group 3: Market Potential - Given the broad clinical demand for aldosterone synthase inhibitors, SYH2072 holds high clinical development value and is expected to provide new treatment options for patients with uncontrolled hypertension and primary aldosteronism [1]
石药集团(01093)：强效醛固酮合成酶抑制剂(SYH2072片)在中国获临床试验批准